Bristol Myers Squibb Co BMY Stock Forecast
AI-powered price prediction and analysis for Bristol Myers Squibb Co · Alpha · vs marketSwitch to Total
See BMY's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Bristol Myers Squibb Co
Bristol Myers Squibb Co (BMY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where BMY sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| BMY Bristol Myers Squibb Co | $127.02B | 13.8x | |
| LLY Eli Lilly & Co | $1.27T | 44.0x | |
| JNJ Johnson & Johnson | $664.95B | 42.0x | |
| ABBV Abbvie Inc. | $518.30B | 44.9x | |
| MRK Merck & Co., Inc. | $362.01B | 151.3x | |
| NVS Novartis Ag | $310.17B | 9.8x | |
| AZN Astrazeneca Plc | $293.55B | 13.7x | |
| ABT Abbott Laboratories | $192.16B | 39.1x | |
| NVO Novo Nordisk A S | $179.14B | 3.0x | |
| PFE Pfizer Inc | $167.51B | 37.2x | |
| VRTX Vertex Pharmaceuticals Inc / … | $138.67B | 35.2x | |
| SNY Sanofi | $115.97B | – | |
| GSK Gsk Plc | $101.54B | 5.6x | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | 20.0x | |
| TAK Takeda Pharmaceutical Co Ltd | $65.66B | 6.3x | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | 41.0x | |
| ONC Beone Medicines Ltd. | $46.26B | 1130.5x | |
| GMAB Genmab A/S | $34.50B | 2.2x | |
| ZTS Zoetis Inc. | $32.81B | 13.5x | |
| RPRX Royalty Pharma Plc | $28.82B | 47.1x | |
| ROIV Roivant Sciences Ltd. | $28.08B | – | |
| INSM Insmed Inc | $25.10B | – | |
| UTHR United Therapeutics Corp | $24.11B | 21.2x | |
| VTRS Viatris Inc | $22.87B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | 7.4x | |
| ASND Ascendis Pharma A/S | $17.07B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | 77.5x | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | – | |
| SMMT Summit Therapeutics Inc. | $13.03B | – | |
| ELAN Elanco Animal Health Inc | $12.86B | – | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | 16.4x | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | 571.8x | |
| TGTX Tg Therapeutics, Inc. | $9.49B | 22.6x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.23B | – | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | – | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | 33.6x | |
| CORT Corcept Therapeutics Inc | $8.11B | 44.9x | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | – | |
| ALKS Alkermes Plc. | $7.75B | 44.8x | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | – | |
| CYTK Cytokinetics Inc | $7.46B | – | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.37B | 86.9x | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | – | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | – | |
| ABVX Abivax S.A. | $6.83B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | – | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | 141.9x | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | – | |
| BLTE Belite Bio, Inc | $6.20B | – | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | 116.9x | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.09B | – | |
| COGT Cogent Biosciences, Inc. | $5.82B | – | |
| MANE Veradermics, Inc | $5.80B | – | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | – | |
| ERAS Erasca, Inc. | $5.04B | – | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | 5.4x | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.81B | – | |
| TVTX Travere Therapeutics, Inc. | $4.44B | – | |
| LEGN Legend Biotech Corp | $4.33B | – |
FAQ
Is Bristol Myers Squibb Co a good stock to buy?
Our AI analyzes Bristol Myers Squibb Co daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Bristol Myers Squibb Co predictions?
For BMY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Bristol Myers Squibb Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 10, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Bristol Myers Squibb Co? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.